Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Роль серотонинэргической системы в формировании легочной артериальной гипертензии у детей с врожденными пороками сердца

Link: Clinical Physiology of Blood Circulaiton. 2007; (): -

Full text:  

Abstract

Plasma and platelet levels of serotonin and 5-hydroxyindolacetic acid (5-HIAA) were measured by highperformance liquid chromatography in children with congenital heart diseases. Plasma serotonin and 5-HIAA levels were increased in pulmonary arterial hypertension (PAH) patients. There was a positive correlation between a degree of PAH and plasma levels of 5-HIAA.

References

1. Горбачевский С. В., Шмальц А. А., Горчакова А. И. Причины и темпы развития легочно-сосудистой болезни при функционально единственном желудочке // Дет. бол. сердца и сосудов. - 2006. - № 4. - С. 44-50.
2. Климович Л. Г., Белкина М. В., Самсонова Н. Н., Горбачевский С. В. Физиологические антикоагулянты, маркеры фибринолиза и реологические свойства крови у больных с ВПС, осложненными легочной гипертензией // Там же. - 2006. - № 4. - С. 28-32.
3. Callebert J., Esteve J. M., Herve P. et al. Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine (2B) receptors in mice // J. Pharmacol. Exp. Ther. - 2006. - Vol. 317, № 2. - P. 724-731.
4. Cote F., Fligny C., Fromes Y. Recent advances in understanding serotonin regulation of cardiovascular function // Trends in Mol. Med. - 2004. - Vol. 10. - P. 232-238.
5. Da Prada M., Picotti G. B. Content and subcellular localization of catecholamines and 5-hydroxytryptamine in human and animal blood platelets: monoamine distribution between platelets and plasma // Brit. J. Pharmacol. - 1979. - Vol. 65, № 4. - P. 653-662.
6. Egermayer P., Town G. I., Peacock A. J. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension // Thorax. - 1999. - Vol. 54, № 2. - P. 161-168.
7. Galie N., Torbicki A. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension // Eur. Respir. J. - 2004. - Vol. 25. - P. 2243-2278.
8. Gillis C. N., Pitt B. R. The fate of circulating amines within the pulmonary circulation //Ann. Rev. Physiol. - 1982. - Vol. 44. - P. 269-281.
9. Herve P., Drouet L., Dosquet C. et al. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin // Amer. J. Med. - 1990. - Vol. 89, № 1. - P. 117-120.
10. Herve P., Launay J. M., Scrobohaci M. L. et al. Increased plasma serotonin in primary pulmonary hypertension // Ibid. - 1995. - Vol. 99, № 3. - P. 249-254.
11. Horibe E., Nishigaki K., Minatoguchi S., Fujiwara H. Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioninglike effect in patients with coronary artery disease // Circ. J. - 2004. - Vol. 68,№ 1. - P. 68-72.
12. Hosoda Y. Pathology of pulmonary hypertension: a human and experimental study // Pathol. Int. - 1994. - Vol. 44, № 4. - P. 241-267.
13. Houkin K., Nakayama N., Nonaka T., Koyanagi I. The 5-hydroxytryptamine2A receptor antagonist sarpogrelate hydrochloride inhibits acute platelet aggregation in injured endothelium // J. Int. Med. Res. - 2006. - Vol. 34, № 1. - P. 65-72.
14. Kereveur A., Callebert J., Humbert M. et al. // Arteriosclerosis, thrombosis, vascular biology. - 2000. - № 20. - P. 2233-2240.
15. Michel P., Hu F., Meyrick B. O. Myoendothelial junctional complexes in postobstructive pulmonary vasculopathy: a quantitative electron microscopic study // Exp. Lung. Res. - 1995. - Vol. 21, № 3. - P. 437-452.
16. Pakala R., Benedict C. R. Effect of serotonin and thromboxane A2 on endothelial cell proliferation: effect of specific receptor antagonists // J. Lab. Clin. Med. - 1998. -Vol. 131. - P. 527-537.
17. Pakala R., Willerson J. T., Benedict C. R. Effect of serotonin, thromboxane A2, and specific antagonists on vascular smooth muscle cell proliferation // Circ. - 1997. - Vol. 96. - P. 2280-2286.
18. Pakala R., Willerson J. T., Benedict C. R. Mitogenic effect of serotonin on vascular endothelial cells // Circulation. - 1994. - Vol. 90, № 4. - P. 1919-1926.
19. Rajesh K. G., Suzuki R., Maeda H. et al. 5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury // Life Sci. - 2006. - Vol. 27, № 79 (Pt. 18). - P. 1749-1755.
20. Reefhuis J., Rasmussen S. A., Friedman J. M. et al. Selective Serotonin-Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn // N. Engl. J. Med. - 2006. - Vol. 354. - P. 2188-2190.
21. Rothman R. B., Ayestas M. A., Dersch C. M. et al. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension // Circulation. - 1999. - Vol. 100, № 8. - P. 869-875.
22. Schranz D. Pulmonale Hypertension im Kindes-und Jugendalter // Monatsschr. Kinder-heilkd. - 2003. - Bd. 151. - S. 424-441.
23. Suhara T., Sudo Y., Yoshida K. et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions // Lancet. - 1998. - Vol. 351, № 9099. - P. 332-335.
24. Zhu C. B., Hewlett W. A., Francis S. H. et al. Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil // Eur. J. Pharmacol. - 2004. - Vol. 504, № 1-2. - P. 1-6.

 If you found mistakes, select text and press Alt+A